Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16506642 | 0.86 | ALDH1A1 (0.39) | PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2 | |
| SCHEMBL16506448 | 0.84 | ALDH1A1 (0.36) | PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2 | |
| SCHEMBL474339 | 0.72 | CYP1A2 (0.55) | PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2 | |
| SCHEMBL29798837 | 0.72 | CYP1A2 (0.55) | PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2 | |
| SCHEMBL975060 | 0.71 | GPR3 (0.44) | ALDH1A1HSD17B10KDM4EHTTMEN1 | |
| SCHEMBL975434 | 0.71 | GPR3 (0.44) | ALDH1A1HSD17B10KDM4EHTTMEN1 | |
| SCHEMBL1450538 | 0.71 | BRPF1 (0.55) | PIK3CDPIK3CAPIK3CBPIK3CGBRD4 | |
| SCHEMBL687655 | 0.71 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1KDM4ECYP1A2LMNA | |
| SCHEMBL4198329 | 0.71 | BRPF1 (0.55) | PIK3CDPIK3CAPIK3CBPIK3CGBRD4 | |
| Hydrochloric Acid SCHEMBL30293270 | 0.70 | CYP1A2 (0.53) | PIK3CDPIK3CAPIK3CBPIK3CGSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115867277-A | Novel fused heterocyclyl-carbohydrazone acyldinitrile compounds and use thereof | 韩国科学技术研究院 | 2023-03-28 | — | — | CN | claimed |
| EP-1968972-B1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-11-28 | — | — | EP | claimed |
| US-8110570-B2 | Modulators of acetyl-coenzyme A carboxylase and methods of use thereof | CROPSOLUTION, INC. (US) | 2012-02-07 | — | — | US | claimed |
| JP-2011528034-A | — | — | 2011-11-10 | — | — | JP | claimed |
| US-7956074-B2 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-06-07 | — | — | US | claimed |
| EP-2310015-A1 | MODULATORS OF ACETYL-COENZYME A CARBOXYLASE AND METHODS OF USE THEREOF | Cropsolution, Inc. (US) | 2011-04-20 | — | — | EP | claimed |
| WO-2010008521-A1 | MODULATORS OF ACETYL-COENZYME A CARBOXYLASE AND METHODS OF USE THEREOF | CROPSOLUTION, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | CROPSOLUTION, INC. | 2010-01-14 | — | — | US | claimed |
| US-20090197875-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | BUETTELMANN BERND | 2009-08-06 | — | — | US | claimed |
| EP-1968972-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-09-17 | — | — | EP | claimed |
| US-20070161686-A1 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | claimed |
| WO-2007071598-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-28 | — | — | WO | claimed |
| EP-0462831-B1 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LTD (GB) | 1996-02-28 | — | — | EP | claimed |
| EP-0462812-B1 | Pyran derivatives as inhibitors of 5-lipoxygenase | ZENECA LTD (GB) | 1995-12-06 | — | — | EP | claimed |
| US-5179115-A | Antiinflammatory agents, antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-01-12 | — | — | US | claimed |
| EP-0462831-A2 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | claimed |
| EP-0462812-A2 | Pyran derivatives as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | claimed |
| WO-2024009308-A1 | TRPV2 CHANNEL BLOCKERS AND USE THEREOF | ICHILOV TECH LTD. (IL) | 2024-01-11 | — | — | WO | disclosed |
| EP-0462830-A2 | Cyclic ether derivatives | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |
| EP-0462831-A2 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197875-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | GABRA5, GABRA4, GABRA3 | PIK3CD 2280/4885PIK3CA 2796/4885PIK3CB 2778/4885 |
| US-20070161686-A1 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | GABRA5, GABRA4, GABRA3 | PIK3CD 2280/4885PIK3CA 2796/4885PIK3CB 2778/4885 |
| US-20100009982-A1 | Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof | ACACA, ACAT1, ACACB | PIK3CD 2132/4885PIK3CA 1144/4885PIK3CB 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.